Barometer Capital Management Inc. boosted its stake in shares of Celgene Co. (NASDAQ:CELG) by 722.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 44,400 shares of the biopharmaceutical company’s stock after buying an additional 39,000 shares during the period. Barometer Capital Management Inc.’s holdings in Celgene were worth $5,525,000 as of its most recent filing with the SEC.

Other large investors have also recently made changes to their positions in the company. PICTET BANK & TRUST Ltd boosted its stake in shares of Celgene by 16.5% in the third quarter. PICTET BANK & TRUST Ltd now owns 35,445 shares of the biopharmaceutical company’s stock valued at $3,705,000 after buying an additional 5,025 shares during the last quarter. Headinvest LLC bought a new stake in shares of Celgene during the fourth quarter worth about $2,667,000. Sawgrass Asset Management LLC bought a new stake in shares of Celgene during the third quarter worth about $31,970,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its stake in shares of Celgene by 3.1% in the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 346,882 shares of the biopharmaceutical company’s stock worth $36,260,000 after buying an additional 10,568 shares during the last quarter. Finally, Hellman Jordan Management Co. Inc. MA boosted its stake in shares of Celgene by 26.7% in the third quarter. Hellman Jordan Management Co. Inc. MA now owns 14,235 shares of the biopharmaceutical company’s stock worth $1,454,000 after buying an additional 3,000 shares during the last quarter. 77.68% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Celgene Co. (NASDAQ:CELG) traded down 0.23% during midday trading on Friday, hitting $117.13. The stock had a trading volume of 960,622 shares. Celgene Co. has a 52 week low of $94.42 and a 52 week high of $127.64. The company’s 50 day moving average price is $122.82 and its 200-day moving average price is $119.25. The stock has a market capitalization of $91.46 billion, a price-to-earnings ratio of 43.98 and a beta of 1.74.

Celgene (NASDAQ:CELG) last announced its earnings results on Thursday, April 27th. The biopharmaceutical company reported $1.68 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.47 by $0.21. The company had revenue of $2.96 billion during the quarter, compared to the consensus estimate of $3.04 billion. Celgene had a net margin of 17.80% and a return on equity of 77.95%. Celgene’s revenue was up 17.8% compared to the same quarter last year. During the same period last year, the firm earned $1.32 earnings per share. Equities analysts anticipate that Celgene Co. will post $7.28 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.thecerbatgem.com/2017/05/19/celgene-co-celg-shares-bought-by-barometer-capital-management-inc-updated.html.

CELG has been the subject of a number of recent analyst reports. Oppenheimer Holdings Inc. set a $148.00 target price on Celgene and gave the stock a “buy” rating in a research report on Friday, February 17th. Cann reiterated a “buy” rating on shares of Celgene in a report on Thursday, January 26th. Vetr lowered Celgene from a “strong-buy” rating to a “buy” rating and set a $132.02 price target for the company. in a report on Thursday, February 16th. Zacks Investment Research upgraded Celgene from a “hold” rating to a “buy” rating and set a $127.00 price target for the company in a report on Wednesday, February 1st. Finally, BTIG Research reiterated a “buy” rating and set a $138.00 price target on shares of Celgene in a report on Monday, January 30th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, twenty have given a buy rating and one has issued a strong buy rating to the stock. Celgene currently has an average rating of “Buy” and an average target price of $138.53.

In other Celgene news, Director James J. Loughlin sold 9,250 shares of the firm’s stock in a transaction on Monday, May 1st. The shares were sold at an average price of $124.00, for a total value of $1,147,000.00. Following the completion of the transaction, the director now owns 32,169 shares of the company’s stock, valued at $3,988,956. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Rupert Vessey sold 4,000 shares of the firm’s stock in a transaction on Wednesday, March 1st. The stock was sold at an average price of $124.42, for a total transaction of $497,680.00. Following the completion of the transaction, the insider now directly owns 778 shares of the company’s stock, valued at approximately $96,798.76. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 27,283 shares of company stock valued at $3,382,386. 0.97% of the stock is owned by insiders.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

5 Day Chart for NASDAQ:CELG

Receive News & Stock Ratings for Celgene Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Co. and related stocks with our FREE daily email newsletter.